We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: LoneStar Heart is Focused on Preserving & Restoring Heart Functions to Heart Failure Patients
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Specialties > Cardiology > LoneStar Heart is Focused on Preserving & Restoring Heart Functions to Heart Failure Patients
BusinessCardiologyNewsTechnology

LoneStar Heart is Focused on Preserving & Restoring Heart Functions to Heart Failure Patients

HerinaAyot
HerinaAyot
Share
5 Min Read
SHARE

LoneStar Heart, Inc.

LoneStar Heart, Inc. is a Texas and California-based biomedical company focused on developing technologies and therapies to preserve and restore heart functions to patients with congestive heart failure (CHF).

Congestive heart failure affects as many as 5 million Americans and with an aging population, more than half a million patients are diagnosed with the condition each year. The mortality rate for CHF is about 10 percent per year.

Lonestar Heart, (a privately held company) takes a “global approach” in their research and development by investigating implantable biopolymers, cardiac stem cell modulators alongside cell and gene therapies. In addition to acquiring and developing a number of intellectual properties, the company has developed a network of international thought leading scientists, clinicians and business partners.

More Read

Healthcare Professionals
PPC Marketing Dos and Don’ts for Healthcare Professionals
Social Media’s Effect on HIPAA Privacy and Security
Choosing the Right mHealth Tools for the Job
13th Annual Global Investment HealthCare Conference
Entering a New Era for Clinical Computing and Patient Engagement

Some of their recent developments include:

  • defining the cardiogenic pathway – from stem cell to heart muscle;
  • reprogramming cells by switching genes and gene combinations “on” and “off”;
  • identifying microenvironments where cardiac stem cells reside;
  • screening and validating biologics and drugs that can control cardiac cell fate; and
  • implanting biopolymer scaffolds for therapeutic use – alone to provide mechanical relief to the muscle or in combination with proteins, peptides or drugs to promote tissue regeneration.

LoneStar’s lead product candidate, Algisyl-LVR, which is under clinical development, is intended to prevent or reverse CHF in patients with an enlarged left ventricle due to mitral valve regurgitation (the mitral valve not closing all the way and blood backflows into the heart), ischemia (heart blockage), dilated cardiomyopathy (left ventricle enlargement) as well as other cardiac disorders.

Algisyl-LVR is made up of an injectable proprietary biopolymer that is placed strategically in areas of the left ventricle muscle. The biopolymer thickens and becomes a permanent implant in the heart muscle. Acting as a prosthetic scaffold, the product aids in a number of long-term benefits including muscle wall thickening, chamber size reduction, decreased local muscle wall stress, reshaping of the dilated ventricle (based on implant location) and realignment of the papillary muscles.

LoneStar Heart is testing two product versions – one for cardiothoracic surgeons to use in traditional open chest surgeries (bypass or valve repairs) or through a minimally invasive standalone procedure. This product will be injected via a standard syringe with a custom needle system. The other version of the product will be offered to heart failure patients through a standalone, noninvasive procedure performed by interventional cardiologists.

 In addition to their implant products, LoneStar Heart is working on a number of other advancements in the treatment of heart failure. Here are a few highlights:

Cardiac Stem Cell Modulators – The scientific teams at LoneStar Heart have identified mechanisms that trigger native cardiac stem cells to regenerate the cardiac muscle. Researchers at the University of Texas Southwestern Medical Center have screened and validated a number of small molecule drugs (in vitro) to switch the stem behavior into a tissue-regenerative mode. LoneStar Heart will work closely with UTSWMC in the advancement of these regenerative drugs.

Regenerative Cell Induction – Under this program, LoneStar Heart is investigating how genes and gene transcription factors may induce a much broader population of cells such as fibroblasts to become cardiac muscle cells. An example of this investigative therapy is the research on skin fibroblasts being manipulated to become stem cells with virtually the same characteristics as embryonic stem cells. The next stage is to see how these cells work in the case of tissue regeneration.

Biomaterials Program – The LoneStar bioengineering team is continuing to develop biopolymers that can be combined with drugs, peptides, proteins or cells to form a bioreactive scaffold. The aim of these developmens is to provide short-term heart muscle stress reduction and a longer-term mechanism for releasing bioreactive substances of therapeutic benefit in localized parts of the heart muscle.

LoneStar Heart will be presenting its products and technologies at OneMedForum SF 2012, on January 9 – 12.

 

TAGGED:CHFcongestive heart failureLone Star Heart
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

The Disconnect Between Hospital Marketing and What Patients Need

March 6, 2012

How SlideShare Can Increase Your Hospital’s Credibility

June 27, 2014
News

LifeBridge Health Lends a Helping Hand to Hurricane Sandy Survivors

November 15, 2012
medical costs with healthcare transparency save 36 billion
Finance

Medical Costs Could Fall by $36 Billion Annually With Price Transparency

June 20, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?